LAVA Therapeutics N.V. (LVTX)
1.740
0.00 (0.00%)
Inactive · Last trade price on Nov 20, 2025
LAVA Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 4.99 | 11.98 | 6.77 | 19.39 | 5.35 | 3.75 | |
Revenue Growth (YoY) | -32.06% | 77.01% | -65.09% | 262.45% | 42.78% | - |
Cost of Revenue | - | - | 3.48 | - | - | 15.7 |
Gross Profit | 4.99 | 11.98 | 3.29 | 19.39 | 5.35 | -11.95 |
Selling, General & Admin | 13.94 | 13.23 | 14.12 | 14.12 | 12.02 | 2.72 |
Research & Development | 12.6 | 24.55 | 32.56 | 40.11 | 36.95 | - |
Operating Expenses | 26.54 | 37.78 | 46.68 | 54.23 | 48.96 | 2.72 |
Operating Income | -21.55 | -25.79 | -43.39 | -34.84 | -43.61 | -14.67 |
Interest Expense | -0.25 | -0.52 | -0.47 | - | -0.63 | -0.34 |
Interest & Investment Income | 2.72 | 3.76 | 3.67 | 0.26 | - | - |
Currency Exchange Gain (Loss) | -0.82 | 1.97 | -1.42 | 2.92 | 2.04 | -0.87 |
EBT Excluding Unusual Items | -19.9 | -20.58 | -41.61 | -31.66 | -42.2 | -15.88 |
Merger & Restructuring Charges | -7.8 | -3.9 | - | - | - | - |
Pretax Income | -22.5 | -24.48 | -41.61 | -31.66 | -42.2 | -15.88 |
Income Tax Expense | 0.68 | 0.63 | 0.26 | 0.25 | 0.16 | 0.04 |
Net Income | -23.18 | -25.11 | -41.87 | -31.91 | -42.36 | -15.93 |
Net Income to Common | -23.18 | -25.11 | -41.87 | -31.91 | -42.36 | -15.93 |
Shares Outstanding (Basic) | 27 | 27 | 27 | 26 | 20 | 0 |
Shares Outstanding (Diluted) | 27 | 27 | 27 | 26 | 20 | 0 |
Shares Change (YoY) | -0.86% | 0.38% | 3.12% | 31.21% | 4850.36% | -10.81% |
EPS (Basic) | -0.86 | -0.94 | -1.57 | -1.23 | -2.14 | -39.90 |
EPS (Diluted) | -0.86 | -0.94 | -1.57 | -1.23 | -2.14 | -39.90 |
Free Cash Flow | -30.76 | -19.57 | -41.01 | 3.46 | -29.41 | -9.81 |
Free Cash Flow Per Share | -1.14 | -0.73 | -1.53 | 0.13 | -1.49 | -24.58 |
Gross Margin | 100.00% | 100.00% | 48.56% | 100.00% | 100.00% | - |
Operating Margin | -431.92% | -215.26% | -641.07% | -179.66% | -815.20% | -391.59% |
Profit Margin | -464.59% | -209.60% | -618.57% | -164.55% | -791.68% | -425.06% |
Free Cash Flow Margin | -616.35% | -163.30% | -605.91% | 17.82% | -549.74% | -261.78% |
EBITDA | -21.33 | -25.33 | -42.78 | -34.33 | -43.28 | -14.46 |
EBITDA Margin | - | -211.37% | - | -177.06% | - | - |
D&A For EBITDA | 0.23 | 0.47 | 0.61 | 0.5 | 0.33 | 0.21 |
EBIT | -21.55 | -25.79 | -43.39 | -34.84 | -43.61 | -14.67 |
EBIT Margin | - | -215.26% | - | -179.66% | - | - |
Revenue as Reported | 4.99 | 11.98 | 6.77 | - | - | 3.75 |